Navigation Links
EnduRx Pharmaceuticals to Present at 2013 Rocky Mountain Life Science Investor and Partnering Conference
Date:8/27/2013

(PRWEB) August 27, 2013

EnduRx Pharmaceuticals, Inc. has been selected to present at the 2013 Rocky Mountain Life Science Investor and Partnering Conference. The conference will take place on September 18-19, 2013 in Denver, Colorado and is hosted by the Colorado BioScience Association. EnduRx Pharmaceuticals is one company chosen to present among thirty from Colorado, Arizona, Utah, Montana, and New Mexico.

         EnduRx Pharmaceuticals, Inc. is a subsidiary of ACTUS Biotechnologies, Inc., an accelerator focused on development of novel technologies into commercially available therapies. The EnduRx Pharmaceuticals platform technology is based upon a modular, multivalent nanotechnology that can be designed to selectively home to vascular tumors, clots, or wounds. The initial use of the platform is focused on the therapeutic treatment of Glioblastoma multiforme (GBM). In pre-clinical models, Endurx Pharmaceuticals’ nanosystem resulted in a 90% success rate in definitive treatment of glioblastoma. Additionally, the system has demonstrated 90% tumor volume reduction in breast cancer, with similar results in prostate cancer, and has proven ability to target a variety of solid vascular tumors. Other uses of the platform technology include atherosclerosis and clots involved in heart attack and stroke, as well as imaging potential in both cancer and cardiovascular disease. EnduRx Pharmaceuticals is currently seeking partners to utilize its proprietary technology to develop the platform in these other indications, using the company’s proof of concept experiments as a basis for development.

         EnduRx Pharmaceuticals, Inc. was founded in 2011 on the basis of proprietary targeting nanoworm technology developed by Dr. Erkki Ruoslahti and his laboratory at the Sanford-Burnham Medical Research Institute ("SBMRI"). Dr. Ruoslahti is among the world's 50 most-cited researchers and an influential figure in cell biology and cancer research. Dr. Ruoslahti’s work has clarified many of the fundamental mechanisms responsible for clinically relevant problems, including tumor metastasis, blood clotting and immune cell homing. His research spawned many drug-discovery programs, some of which have resulted in FDA-approved drugs.

         For more information on EnduRx Pharmaceuticals, visit the company’s website here. Information regarding ACTUS Biotechnologies may be found at the company’s website, here. Additional information on the Rocky Mountain Life Science Investor and Partnering Conference can be found here.

Read the full story at http://www.prweb.com/releases/2013/8/prweb11063745.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
2. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
3. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
4. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
5. Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
6. Acumen Pharmaceuticals Regains Worldwide Rights to Anti-ADDL Antibody Therapeutics and Diagnostics for Alzheimers Disease From Merck
7. Inspiration Biopharmaceuticals Moves Corporate Headquarters to Cambridge, Massachusetts
8. Ampio Pharmaceuticals Awarded Canadian Composition of Matter Patent That Strengthens IP Protection for Its Key Drug Ampion™
9. Amylin Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
10. Inovio Pharmaceuticals Promotes Niranjan Sardesai to Chief Operating Officer
11. Keryx Biopharmaceuticals to Present at JP Morgans 30th Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... While things have been quiet for ... company and provide a new outlook for the future. As a continued effort ... management with the retirement of Mr. Siegel as CEO. With the new adjustments in ...
(Date:4/27/2017)... ... April 27, 2017 , ... ... digital pathology, today announced their digital pathology technology has the potential to eliminate ... five medical centers in The Netherlands as part of the 2017 ISBI ...
(Date:4/27/2017)... ... April 27, 2017 , ... During the course ... how testing for 1,25-Dihydroxyvitamin D can enhance clinical practice. Participants will learn the ... dihydroxyvitamin D. , Dr. Gregory Plotnikoff, senior consultant with Minnesota Personalized Medicine, will ...
(Date:4/27/2017)... ... 27, 2017 , ... The Council for Agricultural Science and ... Lusk, a consummate communicator who promotes agricultural science and technology in the public ... explains how innovation and growth in agriculture are critical for food security and ...
Breaking Biology Technology:
(Date:4/11/2017)... Florida , April 11, 2017 ... a security technology company, announces the appointment of independent Directors ... Bendheim to its Board of Directors, furthering the company,s ... ... of NXT-ID, we look forward to their guidance and benefiting ...
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/5/2017)... KEY FINDINGS The global market ... CAGR of 25.76% during the forecast period of 2017-2025. ... for the growth of the stem cell market. ... MARKET INSIGHTS The global stem cell market is segmented ... The stem cell market of the product is segmented ...
Breaking Biology News(10 mins):